High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Amatu A, Schirripa M, Tosi F, Lonardi S, Bencardino K, Bonazzina E, Palmeri L, Patanè DA, Pizzutilo EG, Mussolin B, Bergamo F, Alberti G, Intini R, Procaccio L, Arese M, Marsoni S, Nichelatti M, Zagonel V, Siena S, Bardelli A, Loupakis F, Di Nicolantonio F, Sartore-Bianchi A, Barault L

Open source

DOI: 10.3389/fonc.2019.00622
Published: 2019
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2019.00622,
  title = {High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.},
  author = {Amatu A and Schirripa M and Tosi F and Lonardi S and Bencardino K and Bonazzina E and Palmeri L and Patanè DA and Pizzutilo EG and Mussolin B and Bergamo F and Alberti G and Intini R and Procaccio L and Arese M and Marsoni S and Nichelatti M and Zagonel V and Siena S and Bardelli A and Loupakis F and Di Nicolantonio F and Sartore-Bianchi A and Barault L},
  year = {2019},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2019.00622},
  url = {https://doi.org/10.3389/fonc.2019.00622}
}

RIS

TY  - JOUR
TI  - High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
AU  - Amatu A
AU  - Schirripa M
AU  - Tosi F
AU  - Lonardi S
AU  - Bencardino K
AU  - Bonazzina E
AU  - Palmeri L
AU  - Patanè DA
AU  - Pizzutilo EG
AU  - Mussolin B
AU  - Bergamo F
AU  - Alberti G
AU  - Intini R
AU  - Procaccio L
AU  - Arese M
AU  - Marsoni S
AU  - Nichelatti M
AU  - Zagonel V
AU  - Siena S
AU  - Bardelli A
AU  - Loupakis F
AU  - Di Nicolantonio F
AU  - Sartore-Bianchi A
AU  - Barault L
PY  - 2019
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2019.00622
UR  - https://doi.org/10.3389/fonc.2019.00622
ER  -

APA

A, A., M, S., F, T., S, L., K, B., E, B., L, P., DA, P., EG, P., B, M., F, B., G, A., R, I., L, P., M, A., S, M., M, N., V, Z., S, S., A, B., F, L., F, D. N., A, S., & L, B. (2019). High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.. Frontiers in oncology. https://doi.org/10.3389/fonc.2019.00622

Source records

pubmed · retrieved 2026-09-25T22:21:04.885Z